Excess adiposity, particularly increases in visceral fat, play a pivotal role in the
pathophysiology of heart failure with preserved ejection fraction (HFpEF). 1 Medicines …

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Obesity remains one of the leading risk factors for the development of heart failure (HF),
which is largely attributable to alterations in cardiac structure and function and a reduced …

The glifozins have become an integral part of the treatment of heart failure [1]. Following the
results of the DAPA-HF trial [2] which were soon followed by EMPEROR-Reduced trial [3] …

Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …

We read with great interest the article by Selvaraj et al1 reporting the changes in metabolic
pathways induced by SGLT2i (sodium-glucose cotransporter-2 inhibitors) in the DEFINE-HF …

Despite significant advances, heart failure remains a significant cause of death and disability
worldwide. Unfortunately, the problem is growing and accordingly the cost of chronic care …

We thank Monzo and Melenovsky for their interest and comments on our study, which
evaluated the association of metabolites and related pathways with several prespecified …

Abstract In the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart
Failure) trial reported by McMurray et al.(Nov. 21 issue), 1 among patients with heart failure …

In the PRESERVED-HF trial, 324 patients with heart failure with preserved ejection fraction
(HFpEF) were randomly assigned to receive dapagliflozin (a sodium–glucose cotransporter …